Clinical Trial Update: First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line everolimus with or without paclitaxel in cisplatin-ineligible advanced urothelial carcinoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Carcinoma
• Transitional Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Matthew Galsky | Conditions: Transitional Cell Carcinoma, Bladder Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-11-24